ES2101865T3 - Igf-1 para mejorar el estado neural. - Google Patents

Igf-1 para mejorar el estado neural.

Info

Publication number
ES2101865T3
ES2101865T3 ES92917908T ES92917908T ES2101865T3 ES 2101865 T3 ES2101865 T3 ES 2101865T3 ES 92917908 T ES92917908 T ES 92917908T ES 92917908 T ES92917908 T ES 92917908T ES 2101865 T3 ES2101865 T3 ES 2101865T3
Authority
ES
Spain
Prior art keywords
nervous system
central nervous
igf
improve
analogues
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92917908T
Other languages
English (en)
Inventor
Peter Gluckman
Karoly Nikolics
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Auckland Uniservices Ltd
Genentech Inc
Original Assignee
Auckland Uniservices Ltd
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=19923685&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2101865(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Auckland Uniservices Ltd, Genentech Inc filed Critical Auckland Uniservices Ltd
Application granted granted Critical
Publication of ES2101865T3 publication Critical patent/ES2101865T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Color Image Communication Systems (AREA)

Abstract

SE PRESENTA UN METODO PARA TRATAR LAS LESIONES O ENFERMEDADES DEL SISTEMA NERVIOSO CENTRAL QUE PREDOMINANTEMENTE AFECTAN LAS CELULAS NEURONALES GLIA Y/O NO COLINERGICAS QUE SE CARACTERIZA EN QUE COMPRENDE EL PASO DE INCREMENTAR LAS CONCENTRACIONES ACTIVAS DEL FACTOR DE CRECIMIENTO I SIMILAR A LA INSULINA Y/O ANALOGOS DEL MISMO EN EL SISTEMA NERVIOSO CENTRAL DEL PACIENTE. LA INVENCION TAMBIEN SUMINISTRA COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN EL FACTOR DE CRECIMIENTO I SIMILAR A LA INSULINA Y/O ANALOGOS DEL MISMO PARA SU ADMINISTRACION A UN PACIENTE DESPUES DE LOS DAÑOS NEURONALES, DICHAS COMPOSICIONES SON UTILES PARA MINIMIZAR LOS DAÑOS EN EL SISTEMA NERVIOS CENTRAL QUE DE OTRA FORMA SE PRODUCIRIAN SIGUIENDO A LA LESION.
ES92917908T 1991-08-01 1992-08-03 Igf-1 para mejorar el estado neural. Expired - Lifetime ES2101865T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
NZ23921191 1991-08-01

Publications (1)

Publication Number Publication Date
ES2101865T3 true ES2101865T3 (es) 1997-07-16

Family

ID=19923685

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92917908T Expired - Lifetime ES2101865T3 (es) 1991-08-01 1992-08-03 Igf-1 para mejorar el estado neural.

Country Status (9)

Country Link
US (2) US5714460A (es)
EP (1) EP0597033B1 (es)
AT (1) ATE151293T1 (es)
CA (1) CA2114251C (es)
DE (1) DE69218948T2 (es)
DK (1) DK0597033T3 (es)
ES (1) ES2101865T3 (es)
GR (1) GR3023874T3 (es)
WO (1) WO1993002695A1 (es)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6440928B1 (en) 1988-12-06 2002-08-27 Colorado State University Research Foundation Method for treating diabetic neuropathy with NGF
US6723699B1 (en) * 1989-06-05 2004-04-20 Cephalon, Inc. Treating disorders by application of insulin-like growth factors and analogs
US6693076B1 (en) * 1989-06-05 2004-02-17 Cephalon, Inc. Treating disorders by application of insulin-like growth factors and analogs
US6310040B1 (en) * 1991-11-08 2001-10-30 Cephalon, Inc. Treating retinal neuronal disorders by the application of insulin-like growth factors and analogs
US5420112A (en) * 1992-06-12 1995-05-30 Lewis; Michael E. Prevention and treatment of peripheral neuropathy
HU217543B (hu) * 1992-06-12 2000-02-28 Albert Einstein College Of Medicine Of Yeshiva University Eljárás perifériás neuropátia kezelésére és megelőzésére alkalmas gyógyászati készítmények előállítására, valamint inzulinszerű növekedési faktor I-et és kemoterápiás szert tartalmazó gyógyászati készítmények
US20070078089A1 (en) * 1992-07-06 2007-04-05 Ishii Douglas N Method for effecting changes in the central nervous system by administration of IGF-I or IGF-II
SE9301667D0 (sv) * 1993-05-14 1993-05-14 Kabi Pharmacia Ab New use
AU693489B2 (en) * 1993-11-15 1998-07-02 Celtrix Pharmaceuticals, Inc. Method of treating neurological disorders
WO1995017204A1 (en) 1993-12-23 1995-06-29 Auckland Uniservices Limited Composition and methods to improve neural outcome
US6812208B2 (en) 1993-12-23 2004-11-02 Neuronz Ltd. Methods to improve neural outcome
US5656605A (en) * 1994-01-26 1997-08-12 Institute Of Molecular Biology, Inc. Device to promote drug-induced nerve regeneration
SE9402332D0 (sv) * 1994-07-01 1994-07-01 Pharmacia Ab Igf-1
US5728676A (en) * 1994-09-08 1998-03-17 Ciba-Geigy Corporation Use of insulin-like growth factors I and II for inhibition of inflammatory response
US5965531A (en) * 1995-08-31 1999-10-12 National Institutes Of Health Method of reducing perivascular lesions using insulin-like growth factor I
DE69627379T2 (de) * 1995-12-13 2004-02-05 Aurogen Inc., Fort Collins Igf-i and -ii zur behandlung von krankheiten im zentralnervensystem
US6015786A (en) * 1997-02-25 2000-01-18 Celtrix Pharmaceuticals, Inc. Method for increasing sex steroid levels using IGF or IGF/IGFBP-3
US6025368A (en) * 1997-02-25 2000-02-15 Celtrix Pharmaceuticals, Inc. Method for treating the symptoms of chronic stress-related disorders using IGF
US6514937B1 (en) 1997-02-25 2003-02-04 Celtrix Pharmaceuticals, Inc. Method of treating psychological and metabolic disorders using IGF or IGF/IGFBP-3
US6121416A (en) 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
US6420518B1 (en) 1997-04-04 2002-07-16 Genetech, Inc. Insulin-like growth factor agonist molecules
US6187906B1 (en) * 1997-08-11 2001-02-13 Aukland Uniservices Limited Methods to improve neural outcome
WO1999020299A1 (en) * 1997-10-17 1999-04-29 Spencer E Martin Human urinary incontinence and methods of treatment
US6627746B1 (en) 1998-04-17 2003-09-30 Exelixis, Inc. Nucleic acids and proteins of C. elegans insulin-like genes and uses thereof
EP1087782A4 (en) * 1998-06-15 2001-09-12 Neuronz Ltd REGULATION OF TYROSINE HYDROXYLASE
JP2002535967A (ja) * 1999-01-06 2002-10-29 ジェネンテック・インコーポレーテッド インシュリン様成長因子（ｉｇｆ）ｉ変異体
AU762351B2 (en) * 1999-01-06 2003-06-26 Genentech Inc. Insulin-like growth factor (IGF) I mutant variants
AU4503801A (en) * 1999-10-27 2001-06-04 Chiron Corporation Temperature dependent neuronal rescue
ATE389416T1 (de) * 2000-05-16 2008-04-15 Genentech Inc Behandlung von knorpelerkrankungen
ATE463252T1 (de) * 2000-08-29 2010-04-15 Aurogen Inc Methode zur behandlung des zentralnervensystems durch applikation von strukturanaloga von igf
US20030027755A1 (en) * 2000-12-08 2003-02-06 Jian Guan Compositions and methods for the rescue of white matter
CN100439397C (zh) * 2001-02-09 2008-12-03 基因技术股份有限公司 Igf-1的结晶
US6682753B2 (en) * 2001-03-23 2004-01-27 Neuronz Limited Methods for promoting weight gain using GPE-related compounds
US7714020B2 (en) 2001-05-24 2010-05-11 Neuren Pharmaceuticals Limited Treatment of non-convulsive seizures in brain injury using G-2-methyl-prolyl glutamate
US20070004641A1 (en) * 2001-05-24 2007-01-04 Neuren Pharmaceuticals Limited Cognitive enhancement and cognitive therapy using glycyl-L-2-methylprolyl-L-glutamate
US7605177B2 (en) 2001-05-24 2009-10-20 Neuren Pharmaceuticals Limited Effects of glycyl-2 methyl prolyl glutamate on neurodegeneration
EP1401808B1 (en) 2001-05-24 2009-07-08 Neuren Pharmaceuticals Limited Gpe analogs and peptidomimetics
US6861406B2 (en) 2001-09-18 2005-03-01 Bioexpertise, Llc IGF-binding protein-derived peptide
US6914049B2 (en) 2001-09-18 2005-07-05 Bioexpertise, Llc IGF-binding protein-derived peptide or small molecule
US7232798B2 (en) * 2001-11-13 2007-06-19 Tran Loi H Neuroprotection and neuroegenisis by administering cyclic prolyl glycine
GB0202906D0 (en) * 2002-02-07 2002-03-27 Univ London Prevention of myocardial damage
EP2274978B1 (en) 2003-09-12 2015-05-20 Tercica, Inc. Methods for treatment of insulin-like growth factor-I(IGF-I) deficiency
US7192738B2 (en) * 2003-10-03 2007-03-20 Genentech, Inc. IGF binding proteins
US7220729B2 (en) * 2004-05-10 2007-05-22 Academia Sinica Huntington's Disease Treatment
EP1674113A1 (en) 2004-12-22 2006-06-28 F. Hoffmann-La Roche Ag Conjugates of insulin-like growth factor-1 (IGF-1) and poly(ethylene glycol)
WO2006097682A1 (en) * 2005-03-18 2006-09-21 Ucl Business Plc Mechano growth factor peptides and their use
AU2007238608A1 (en) * 2006-04-14 2007-10-25 Massachusetts Institute Of Technology Identifying and modulating molecular pathways that mediate nervous system plasticity
CL2007002502A1 (es) 2006-08-31 2008-05-30 Hoffmann La Roche Variantes del factor de crecimiento similar a insulina-1 humano (igf-1) pegilados en lisina; metodo de produccion; proteina de fusion que la comprende; y su uso para tratar la enfermedad de alzheimer.
JP4958975B2 (ja) 2006-08-31 2012-06-20 エフ．ホフマン−ラ ロシュ アーゲー インスリン様増殖因子ｉの製造方法
CA2689549A1 (en) * 2007-06-08 2008-12-18 Massachusetts Institute Of Technology Igf for the treatment of rett syndrome and synaptic disorders
US20110045510A1 (en) * 2008-04-03 2011-02-24 Kurt Lang Pegylated insulin-like-growth-factor assay
JP5173018B2 (ja) * 2008-04-03 2013-03-27 エフ．ホフマン−ラ ロシュ アーゲー 神経筋障害の処置のためのｐｅｇ化ｉｇｆ−ｉ変異体の使用
US20110152188A1 (en) 2009-12-23 2011-06-23 Hanns-Christian Mahler Pharmaceutical compositions of igf/i proteins
CN106167789B (zh) * 2015-05-21 2020-08-04 中国科学院上海营养与健康研究所 低氧处理的间充质干细胞及其应用
KR102245539B1 (ko) 2018-02-12 2021-04-29 주식회사 지앤피바이오사이언스 코어-쉘 구조의 마이크로 입자를 유효성분으로 포함하는 성장인자 유전자 발현 증가용 조성물
EP3843768A4 (en) 2018-05-15 2022-11-23 Tran, Lloyd Hung Loi THERAPEUTIC COMPOSITION AND METHODS OF USE IN THE TREATMENT OF MILD COGNITIVE IMPAIRMENT, DEPRESSION AND MENTAL DISORDERS
US20210008172A1 (en) 2019-07-11 2021-01-14 Opko Biologics Ltd. Long-acting igf-1 or igf-1 variants and methods of producing same
US12324827B2 (en) 2019-09-09 2025-06-10 The University Of Chicago Combination therapy for the treatment of migraines

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8703625D0 (sv) * 1987-09-18 1987-09-18 Kabivitrum Ab New medical use
US5817623A (en) 1995-03-06 1998-10-06 Univ Colorado State Res Found Method for treating diabetic peripheral neuropathy with IGF-I or IGF-II
US5093317A (en) * 1989-06-05 1992-03-03 Cephalon, Inc. Treating disorders by application of insulin-like growth factor
EP0484416A1 (en) * 1989-07-27 1992-05-13 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Regulation of nerve growth factor synthesis in the central nervous system
US5219837A (en) * 1990-06-21 1993-06-15 Trustees Of The University Of Pennsylvania Method of stimulating myelination of cells
US5861373A (en) * 1991-08-01 1999-01-19 Genentech, Inc IGF-1 to improve the neural condition
US20070078089A1 (en) 1992-07-06 2007-04-05 Ishii Douglas N Method for effecting changes in the central nervous system by administration of IGF-I or IGF-II

Also Published As

Publication number Publication date
DE69218948T2 (de) 1997-07-31
EP0597033B1 (en) 1997-04-09
WO1993002695A1 (en) 1993-02-18
DE69218948D1 (de) 1997-05-15
USRE43982E1 (en) 2013-02-05
CA2114251C (en) 2007-11-06
US5714460A (en) 1998-02-03
DK0597033T3 (da) 1997-06-02
CA2114251A1 (en) 1993-02-18
ATE151293T1 (de) 1997-04-15
EP0597033A1 (en) 1994-05-18
GR3023874T3 (en) 1997-09-30

Similar Documents

Publication Publication Date Title
ES2101865T3 (es) Igf-1 para mejorar el estado neural.
CA2122058A1 (en) Tgf-beta to improve neural outcome
DE68911068T2 (de) EGF zur Vorbeugung von Gewebeschädigung nach Ischemie.
GB9316895D0 (en) Hepatoselective insulin analogues
ES2162615T3 (es) Metodo para tratar o prevenir diabetes de tipo 1 mediante la administracion oral de insulina.
HUT51136A (en) Process for producing pharmaceutical compositions for treating schisophreny, containing l-deprenil as active component
GB9519661D0 (en) Fatty acid treatment
ATE515265T1 (de) Vitamin d und dessen analoge zur behandlung vom tumoren und anderen hyperproliferativen erkrankungen
MY131805A (en) Synergistic composition and methods for treating neoplastic or cancerous growths and for restoring or boosting hematopoiesis.
NO990088D0 (no) Farmas÷ytiske preparater omfattende S-(-)-N-propargyl-1-aminoindamin
DE69533112D1 (de) Verwendung von flavolignanen zur herstellung von medikamenten mit antiproliferativer aktivität in gebärmutter,brust,eierstöcken
DE69230112D1 (de) Fortschrittliches arzneistoffabgabesystem und verfahren zur behandlung von psychiatrischen, neurologischen und anderen erkrankungen mit carbamazepin
EP0798000A3 (en) Treating disorders by application of insulin-like growth factors and analogs
ZA911496B (en) Use of 3-guanidinopropionic acid in the treatment and prevention of metabolic disorders
ATE112684T1 (de) Verwendung von igf-ii zur behandlung von knochenkrankheiten.
GR3031459T3 (en) Wound treatment employing biologically active peptides
PT97785A (pt) Metodo para a tratamento da impotencia utilizando, por exemplo, doxazosina
BR9708287A (pt) Processo para tratar ou prevenir um distúrbio do sistema nervoso central em um ser humano, para eliciar um efeito antiemético em um ser humano e para tratar um estado de doença em um ser humano, composição farmacêutica para tratar de distúrbios do sistema nervoso central em um ser humano, e, forma de dosagem unitária farmacêutica
BR9500436A (pt) Produtos uso de um g-csf uso de uma proteína tnf ligante processo para o tratamento e/ou prevenção do choque séptico
RU94041207A (ru) Средство для лечения заболеваний, поражающих нервную систему
PT817646E (pt) Metodos de tratamento da inflamacao e formulacoes para esse fim
EP0515434A4 (en) Method for treating intestinal diseases
CA2108330A1 (en) Enhancer for the Antianemia Effect of Erythropoietin and Method of Augmenting the Antianemia Effect of Erythropoietin
EP0744176A3 (en) Methods for inhibiting bone loss
CO5031290A1 (es) Formulacion lo

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 597033

Country of ref document: ES